Anti-osteoporosis effect of Gushukang in ovariectomized rats: a lumbar metabonomic analysis

doi:10.12307/2022.937

Abstract

Abstract: BACKGROUND: The research on the specific molecular mechanisms and therapeutic targets of Gushukang on osteoporosis is insufficient, which needs further research and discussion.
OBJECTIVE: To analyze and identify the changes of lumbar metabolites in ovariectomized rats, explore the therapeutic effect of Gushukang on osteoporosis in ovariectomized rats and discuss its potential mechanism by using the non-targeted metabonomics of ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass, thereby to further explore the specific mechanisms and targets of Gushukang in the treatment of osteoporosis.
METHODS: Female Sprague-Dawley rats, which were ovariectomized to establish osteoporosis model, were divided into model group, Gushukang group, and sham operation group. Osteoporotic models were established using ovariectomy. Four weeks after modeling, rats in the Gushukang group were given Gushukang by gavage; and those in the sham operation and model groups were given the equal volume of normal saline. After 12 weeks of continuous gavage, the lumbar metabolites of rats were analyzed by the ultra-performance liquid chromatography coupled with quadrupole time-of-flight tandem mass technology, and the common differential metabolites were selected for bioinformatics analysis using Kyoto Encyclopedia of Genes and Genomes pathway.
RESULTS AND CONCLUSION: A total of 24 common significant differential metabolites were identified in the three groups. Kyoto Encyclopedia of Genes and Genomes enrichment analysis showed that Gushukang could regulate important pathways such as fatty acid metabolism, glycerol phospholipid metabolism and amino acid metabolism, and participate in the protection of bone metabolism in osteoporosis model rats. These findings indicate that Gushukang exerts its anti-osteoporosis effect by interfering with lipid metabolism and amino acid metabolism, so as to achieve the purpose of preventing osteoporosis.

Key words: osteoporosis, metabonomics, Gushukang, lipid metabolism, amino acid metabolism, differential metabolites, mass spectrum, traditional Chinese medicine

CLC Number:

Zhang Haiyong, Huang Jingwen, Xie Bingying, Chen Sainan, Xie Lihua, Chen Xuan, Li Shengqiang, Ge Jirong. Anti-osteoporosis effect of Gushukang in ovariectomized rats: a lumbar metabonomic analysis[J]. Chinese Journal of Tissue Engineering Research, 2022, 26(32): 5185-5190.

Figures/Tables 8

References

[1] 原发性骨质疏松症诊治指南(2011年)[J].中华骨质疏松和骨矿盐疾病杂志,2011,4(1):2-17.
[2] YOSHIMURA N, MURAKI S, NAKAMURA K, et al.Epidemiology of the locomotive syndrome: The research on osteoarthritis/osteoporosis against disability study 2005-2015. Mod Rheumatol. 2017;27(1):1-7.
[3] 中国骨质疏松症流行病学调查及“健康骨骼”专项行动结果发布[J].中华骨质疏松和骨矿盐疾病杂志,2019,12(4):317-318.
[4] 吕遐,扶琼.原发性骨质疏松症的研究进展与最新指南解读[J].临床内科杂志,2020,37(5):319-322.
[5] 许荣权,苏再发.骨质疏松症中医疗法的研究概况[J].中国医药导刊,2020,22(11):772-775.
[6] 葛继荣,王和鸣,郑洪新,等.中医药防治原发性骨质疏松症专家共识(2020)[J].中国骨质疏松杂志,2020,26(12):1717-1725.
[7] 郭宁,宫明,于大鹏.绝经后骨质疏松症应用骨疏康治疗的临床效果研究[J].中外医疗,2015,34(15):156-157.
[8] 张鉴,王亦璜,王文超,等.中药骨舒康治疗绝经后骨质疏松患者的临床效果观察[J].临床合理用药杂志,2017,10(29):56-57.
[9] NICHOLSON JK, LINDON JC, HOLMES E. ‘Metabonomics’: understanding the metabolic responses of living systems to pathophysiological stimuli via multivariate statistical analysis of biological NMR spectroscopic data. Xenobiotica. 1999;29(11):1181-1189.
[10] 陈赛楠,吴华嵩,程佑民,等.续苓健骨方对去卵巢骨质疏松模型大鼠血液钙磷代谢的影响[J].中国骨质疏松杂志,2019,25(4):528-532.
[11] 陈勇.骨疏康胶囊治疗绝经后骨质疏松性转子间骨折的临床效果分析[J].中国骨质疏松杂志,2019,25(11):1571-1575.
[12] 成洁,王颖,吉健华,等.骨疏康胶囊治疗肾阳虚型骨质疏松症疗效及对患者骨代谢影响[J].陕西中医,2019,40(9):1232-1234+1250.
[13] 韩国瑞,董卫兵,明海武.骨疏康胶囊辅助治疗绝经后骨质疏松性股骨转子间骨折的临床效果分析[J].中国合理用药探索,2021,18(6): 86-91.
[14] WANG Q, ZHAO YG, SHA NN, et al. The systemic bone protective effects of Gushukang granules in ovariectomized mice by inhibiting osteoclastogenesis and stimulating osteoblastogenesis. J Pharmacol Sci. 2018;136(3):155-164.
[15] LI WT, ZHOU XQ, JIANG TJ, et al. Positive Effect of Gushukang on Type-H Vessel and Bone Formation. Front Cell Dev Biol. 2020;8:265.
[16] 郑志坚,舒冰,赵世天,等.骨疏康颗粒对去卵巢小鼠骨质疏松模型骨丢失和破骨细胞凋亡的影响[J].中华中医药杂志,2020,35(7): 3647-3651.
[17] LI XL, WANG L, BI XL, et al. Gushukang exerts osteopreserve effects by regulating vitamin D and calcium metabolism in ovariectomized mice. J Bone Miner Metab. 2019;37(2):224-234.
[18] IDE T, ORIGUCHI I. An Oil Rich in γ-Linolenic Acid Differently Affects Hepatic Fatty Acid Oxidation in Mice and Rats. Biol Pharm Bull. 2020; 43(9):1382-1392.
[19] Ide T, ORIGUCHI I. Physiological effects of an oil rich in γ-linolenic acid on hepatic fatty acid oxidation and serum lipid levels in genetically hyperlipidemic mice. J Clin Biochem Nutr. 2019;64(2):148-157.
[20] 伍海艳,吴荣艳,钟凤元,等.雌激素代谢紊乱对老年女性骨质疏松患者的影响[J].中国老年学杂志,2021,41(12):2567-2569.
[21] 梁胡贞,贲吕金,钟雪群.绝经后骨质疏松症患者血清雌激素水平与前脂肪因子-1及瘦素水平的相关性分析[J].中国实用医药,2020, 15(29):104-106.
[22] 张倩,杨旭,王媛,等.二仙汤对去势大鼠骨微结构及ALP、OPG、IL-6的影响[J].世界中西医结合杂志,2020,15(11):2053-2057+2061.
[23] XUE LM, WANG Y, LIU L, et al. A HNMR-based metabonomics study of postmenopausal osteoporosis and intervention effects of Er-Xian Decoction in ovariectomized rats. Int J Mol Sci. 2011;12(11):7635-7651.
[24] DAI L, FENG Z, ZHA R, et al. Discovery of Novel Peroxisome Proliferator-Activated Receptor α (PPARα) Agonists by Virtual Screening and Biological Evaluation. J Chem Inf Model. 2020;60(3):1717-1727.
[25] 赵晓杰,韩晓群,邓琴,等.PPARγ在结核分枝杆菌感染小鼠脂质代谢中的作用[J].中国病理生理杂志,2021,37(5):849-856.
[26] TORU Y, TOSHITSUG S, SHOZO Y, et al. Plasma Lipids and Osteoporosis in Postmenopausal Women. Endocr J. 2002;49(2):211-217.
[27] KRESS BJ, KIM DH, MAYO JR, et al. Synthesis and Evaluation of PPARδ Agonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis. J Med Chem. 2021;64(10):6996-7032.
[28] SMITH P, OWEN DM, LORENZ CD, et al. Asymmetric glycerophospholipids impart distinctive biophysical properties to lipid bilayers. Biophys J. 2021;120(9):1746-1754.
[29] SHE Y, SONG J, YANG E, et al. Rapid identification of glycerophospholipids from RAW264.7 cells by UPLC/ESI -QTOF-MS. Biomed Chromatogr. 2014;28(12):174417-174455.
[30] LIU XY, LIU YQ, CHENG MC, et al. A metabolomics study of the inhibitory effect of 17-beta-estradiol on osteoclast proliferation and differentiation. Mol Biosyst. 2015;11(2):635-646.
[31] LIU XY, ZHANG SS, LU XM, et al. Metabonomic study on the anti-osteoporosis effect of Rhizoma Drynariae and its action mechanism using ultra-performance liquid chromatography–tandem mass spectrometry. J Ethnopharmacol. 2012;139(1):311-317.
[32] FERNANDES DA SJ, ALVES JV, SILVANETO JA, et al. Lysophosphatidylcholine induces oxidative stress in human endothelial cells via NOX5 activation - implications in atherosclerosis. Clin Sci (London, England : 1979). 2021;135(15):1845-1858.
[33] 彭涛,李爱国,何培亮.绝经后骨质疏松与氧化应激相关研究进展[J].中外医学研究,2020,18(10):186-188.
[34] SOOHO L, HUYNH LN, DONGCHUL K. Melatonin alleviates oxidative stress-inhibited osteogenesis of human bone marrow-derived mesenchymal stem cells through AMPK activation. Int J Med Sci. 2018; 15(10):1083-1091.
[35] XIAO W, BIN C, JING YS, et al. Iron-induced oxidative stress stimulates osteoclast differentiation via NF-κB signaling pathway in mouse model. Metabolism. 2018;83:167-176.
[36] ZHANG AH, MA ZM, SUN H, et al. High-Throughput Metabolomics Evaluate the Efficacy of Total Lignans From Acanthophanax Senticosus Stem Against Ovariectomized Osteoporosis Rat. Front Pharmacol. 2019;10:553.
[37] HE W, LIU M, HUANG XN, et al. The influence of vitamin D receptor genetic variants on bone mineral density and osteoporosis in Chinese postmenopausal women. Dis Markers. 2015;2015:760313
[38] DEYAMA Y, KIKUIRI T, OHNISHI GI, et al. Histamine stimulates production of osteoclast differentiation factor/receptor activator of nuclear factor-kappaB ligand by osteoblasts. Biochem Biophys Res Commun. 2002;298(2):240-246.
[39] NAKAMURA M, KURODA H, NARITA K, et al. Parathyroid hormone induces a rapid increase in the number of active osteoclasts by releasing histamine from mast cells. Life Sci. 1996;58(21):1861-1868.
[40] FITZPATRICK LA, BUZAS E, GAGNE TJ, et al. Targeted Deletion of Histidine Decarboxylase Gene in Mice Increases Bone Formation and Protects against Ovariectomy-Induced Bone Loss. Proc Natl Acad Sci U S A. 2003;100(10):6027-6032.
[41] LIU YZ, DVORNYK V, LU Y, et al. A novel pathophysiological mechanism for osteoporosis suggested by an in vivo gene expression study of circulating monocytes. J Biol Chem. 2005;280(32):29011-20916.
[42] YAMAGUCHI M. beta-Alanyl-L-histidinato zinc and bone resorption. Gen Pharmacol. 1995;26(6):1179-1183.